Loading...
Indian Pharmaceutical Exporter · #11 for Pembrolizumab · $42.5K export value · DGFT Verified
K. K. Pharma Solutions is the #11 Indian exporter of Pembrolizumab with $42.5K in export value and 8 verified shipments. K. K. Pharma Solutions holds a 2.2% market share in Pembrolizumab exports across 1 countries.
| GEORGIA | $150.4K | 9 | 8.2% |
| UNITED KINGDOM | $73.0K | 8 | 4.0% |
| IRAQ | $68.7K | 2 | 3.7% |
| GERMANY | $50.0K | 1 | 2.7% |
| SAINT KITTS AND NEVIS | $33.4K | 4 | 1.8% |
| KENYA | $23.9K | 3 | 1.3% |
India exports Pembrolizumab to 21 countries. The top destination is BRAZIL (46.9%), followed by ZIMBABWE and MALDIVES.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| INDIRA GANDHI MEMORIAL HOSPITAL | MALDIVES | $130.1K | 30 |
| AS PER INVOICE | BRAZIL | $105.6K | 10 |
| MERMISI LLC | GEORGIA | $59.9K | 6 |
| KARLENE SMALL | JAMAICA | $53.3K | 2 |
| F AGAINST PROFORMA INVOICE | BRAZIL | $48.9K | 6 |
| KEISHA YOUNG-HENRY | JAMAICA | $47.8K | 2 |
| RICARDO LUIZ BARBOZA | BRAZIL | $47.4K | 7 |
| ERINEA FERRAZ DOS | BRAZIL | $47.2K | 5 |
| EXP CODE | BRAZIL | $29.5K | 4 |
| ERIKA CARDOSO DA SILVA | BRAZIL | $28.2K | 3 |
India's Pembrolizumab is purchased by 66 buyers worldwide. The top buyer is INDIRA GANDHI MEMORIAL HOSPITAL (MALDIVES), followed by AS PER INVOICE and MERMISI LLC.
India exported $1.7M worth of Pembrolizumab through 215 shipments from 34 suppliers to 21 countries, serving 66 buyers globally. K. K. Pharma Solutions contributes $42.5K to this total, accounting for 2.2% of India's Pembrolizumab exports.
K. K. Pharma Solutions's average Pembrolizumab shipment value is $5.3K per consignment, based on 8 shipments totaling $42.5K.
K. K. Pharma Solutions ranks #11 among 34 Indian Pembrolizumab exporters with a 2.2% market share. The top 3 exporters are GNH INDIA PHARMACEUTICALS LIMITED ($285.3K), GEMINI HEALTHWORLD LLP ($212.6K), 3S PHARMACEUTICALS INDIA PRIVATE LIMITED ($201.7K). K. K. Pharma Solutions processed 8 shipments to 1 destination countries.
What K. K. Pharma Solutions must comply with to export Pembrolizumab to its top destination countries
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #11 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 9 | G P INTERGLOBE | $59.9K | 6 | 1 | $10.0K |
| 10 | DHEER HEALTHCARE PRIVATE LIMITED | $48.9K | 6 | 1 | $8.1K |
| 11 | K. K. PHARMA SOLUTIONS ★ | $42.5K | 8 | 1 | $5.3K |
| 12 | SPR ONCOCARE PRIVATE LIMITED | $26.8K | 3 | 2 | $8.9K |
| 13 | ALLEVIARE LIFE SCIENCES PRIVATE LIMITED | $23.9K | 3 | 1 | $8.0K |
K. K. Pharma Solutions ranks #11 among 34 Indian Pembrolizumab exporters. Average shipment value of $5.3K compared to the market average of $50.2K. The closest competitors by value are G P INTERGLOBE and DHEER HEALTHCARE PRIVATE LIMITED.
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 47 | 21.9% |
| AHEMDABAD AIR ACC (INAMD4) | 33 | 15.3% |
| DELHI AIR CARGO ACC (INDEL4) | 25 | 11.6% |
| DELHI AIR | 19 | 8.8% |
| AHEMDABAD AIR | 17 | 7.9% |
| SAHAR AIR CARGO ACC (INBOM4) | 15 | 7.0% |
| BANGALORE ACC (INBLR4) | 13 | 6.0% |
| BANGALORE AIR | 10 | 4.7% |
Latest developments and market context
Detailed market intelligence for Pembrolizumab — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify manufacturer licensing and export certifications with the official agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 21+ countries, 66+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level details, pricing data, buyer connections, and competitive analysis for K. K. Pharma Solutions's Pembrolizumab exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
K. K. Pharma Solutions
Company Profile
0 products · $0 total trade · 0 categories
Access shipment-level records, pricing trends, and buyer contacts for K. K. Pharma Solutions.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Pembrolizumab. For current shipment-level data, contact TransData Nexus.